Shares of NewLink Genetics Corp. (NASDAQ:NLNK) were down 1.9% during trading on Thursday . The stock traded as low as $11.32 and last traded at $11.36, with a volume of 88,445 shares changing hands. The stock had previously closed at $11.58.

Several analysts have commented on NLNK shares. Stifel Nicolaus dropped their price objective on NewLink Genetics Corp. from $63.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 price objective on shares of NewLink Genetics Corp. in a report on Friday, April 29th. Mizuho dropped their price objective on NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Zacks Investment Research raised NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Tuesday. Finally, Robert W. Baird reissued a “buy” rating on shares of NewLink Genetics Corp. in a report on Monday, May 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $23.29.

The stock has a 50 day moving average price of $11.12 and a 200 day moving average price of $18.75. The stock’s market cap is $340.27 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last posted its earnings results on Friday, April 29th. The company reported ($0.82) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.70) by $0.88. The firm earned $4.34 million during the quarter, compared to analysts’ expectations of $2.08 million. On average, equities research analysts predict that NewLink Genetics Corp. will post ($2.83) EPS for the current fiscal year.

A number of hedge funds recently bought and sold shares of the stock. California State Teachers Retirement System increased its stake in NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock valued at $1,402,000 after buying an additional 636 shares in the last quarter. EQIS Capital Management increased its stake in NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock valued at $1,515,000 after buying an additional 35,587 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock valued at $1,993,000 after buying an additional 31,375 shares in the last quarter. GSA Capital Partners LLP increased its stake in NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock valued at $2,386,000 after buying an additional 3,498 shares in the last quarter. Finally, Russell Frank Co increased its stake in NewLink Genetics Corp. by 57.1% in the fourth quarter. Russell Frank Co now owns 265,422 shares of the company’s stock valued at $9,712,000 after buying an additional 96,512 shares in the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.